The Weekly Summary

Tim-CookJanuary 26th – February 1st

In the general news, the government of Greece is unraveling again, causing the Eurozone problems. In the U.S., Apple inc. earnings were unprecedented in the history of mankind, with $75 Billion in revenue from strong sales of iPhone 6.

In healthcare business news, earnings season continued with biotechs and small caps reporting. Biogen (BIIB) was notably strong, sending shares up 10%.

On the data front, Medtronic (MDT) posted data on CoreValve compared to open heart surgery.

From the FDA, Abiomed (ABMD) won approval for the Impella heart pump, shooting up shares as shorts covered. Rockwell Medical’s (RMTI) iron replacement drug Triferic was approved. Bristol-Myers Squibb’s (BMY) HIV drug Evotaz (a once-daily pill containing Reyataz, also known as atazanavir, a protease inhibitor, with the booster cobicistat) was approved. JNJ had a simlar combo-pill for HIV approved, Prezcobix (which combines protease inhibitor darunavir, or Prezista, with cobicistat). JNJ and Pharmacyclics (PCYC) drug Imbruvica was approved for the additional indication to treat Waldenstrom’s macroglobulinemia. Lastly, the agency approved Shire’s (SHIRE) Vyvanse for binge-eating disorder.

This entry was posted in - The Weekly Summary. Bookmark the permalink.

Leave a Reply

Your email address will not be published.